Q1 FY27 · Ended Jul 31, 2026 · View SEC filing
Cardiovascular earnings equal more than half of operating profit
Pulsed field ablation lifted Cardiovascular sales 19.5%, so a single procedure family now shapes the company's growth and its profit.
For investorsGrowth after the extra week: what the device segments must do alone
For foundersSell the system, and the consumables follow
Gross margin held flat, so the operating margin rise came from research spending growing slower than sales and lower amortization.
Net income rose 41.3% against 22.1% for operating profit, helped by investment gains and a lower tax charge.
Diabetes brings 8.6% of sales, yet its group earns 4.2% of operating profit, so its planned exit would tilt Medtronic toward hospital devices.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Medtronic from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
